Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Acting FDA Head Von Eschenbach Takes A Step Back At NCI

This article was originally published in The Tan Sheet

Executive Summary

FDA Acting Commissioner Andrew von Eschenbach's decision to step away from day-to-day management duties at the National Cancer Institute follows a week of criticism from Capitol Hill related to his dual role

You may also be interested in...



Grassley seeks Commissioner

"The FDA has struggled with temporary leadership for too long," Sen. Charles Grassley (R-Iowa) asserts in a Feb. 3 letter to President Bush's Chief of Staff Andrew Card. "I reiterate my request for the President to nominate a permanent Commissioner to the FDA as soon as possible," states Grassley, who chairs the Senate Finance Committee. Grassley first called for a leader "who can be totally dedicated to the job" when NCI Director Andrew Von Eschenbach assumed the position of acting commissioner in September (1"The Tan Sheet" Oct. 3, 2005, p. 6). FDA "needs and deserves a full-time, permanent Commissioner with the authority to address the cultural, structural and scientific challenges that have plagued the agency," Grassley states. "As has been overwhelmingly evident in the past few years, there are too many concerns and questionable practices that would require anything less"...

Grassley seeks Commissioner

"The FDA has struggled with temporary leadership for too long," Sen. Charles Grassley (R-Iowa) asserts in a Feb. 3 letter to President Bush's Chief of Staff Andrew Card. "I reiterate my request for the President to nominate a permanent Commissioner to the FDA as soon as possible," states Grassley, who chairs the Senate Finance Committee. Grassley first called for a leader "who can be totally dedicated to the job" when NCI Director Andrew Von Eschenbach assumed the position of acting commissioner in September (1"The Tan Sheet" Oct. 3, 2005, p. 6). FDA "needs and deserves a full-time, permanent Commissioner with the authority to address the cultural, structural and scientific challenges that have plagued the agency," Grassley states. "As has been overwhelmingly evident in the past few years, there are too many concerns and questionable practices that would require anything less"...

Grassley seeks Commissioner

"The FDA has struggled with temporary leadership for too long," Sen. Charles Grassley (R-Iowa) asserts in a Feb. 3 letter to President Bush's Chief of Staff Andrew Card. "I reiterate my request for the President to nominate a permanent Commissioner to the FDA as soon as possible," states Grassley, who chairs the Senate Finance Committee. Grassley first called for a leader "who can be totally dedicated to the job" when NCI Director Andrew Von Eschenbach assumed the position of acting commissioner in September (1"The Tan Sheet" Oct. 3, 2005, p. 6). FDA "needs and deserves a full-time, permanent Commissioner with the authority to address the cultural, structural and scientific challenges that have plagued the agency," Grassley states. "As has been overwhelmingly evident in the past few years, there are too many concerns and questionable practices that would require anything less"...

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS098682

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel